Get the Daily Brief
Latest Biotech News
GSK joins MCE race: $50M upfront for LTZ myeloid‑cell engager tech
GSK agreed to an upfront payment for access to LTZ Therapeutics’ myeloid cell engager (MCE) platform, joining other Big Pharma entrants pursuing myeloid‑directed immune‑engager modalities. The...
Roche inks $200M‑plus pact to commercialize Freenome’s cancer screens abroad
Roche agreed to a multiyear collaboration and equity investment with Freenome to commercialize Freenome’s blood‑based cancer screening tests outside the U.S., a deal potentially worth more than...
Administration vaccine proposals roil industry: makers warn of supply shock
U.S. health manufacturers and experts raised alarms after reporting that the administration—led by Health Secretary Robert F. Kennedy Jr.—is weighing major vaccine policy changes, including...
J&J buys Halda — $3.05B bet on RIPTAC oncology
Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash to add Halda’s RIPTAC-derived precision oncology portfolio to J&J’s pipeline. The deal centers on HLD-0915, a...
RNAi reaches market... Arrowhead wins FDA and ignites pricing fight
The FDA approved Arrowhead Pharmaceuticals’ RNAi therapeutic Redemplo (plozasiran) for familial chylomicronemia syndrome (FCS), marking Arrowhead’s entry into the commercial stage and the second...
Roche’s oral SERD delays recurrence — adjuvant Phase III win
Roche reported positive Phase III results showing its oral selective estrogen receptor degrader (SERD) extended invasive disease-free survival versus standard hormone therapy in patients with...
Zanidatamab shines in GEA — Phase III PFS and OS signals
Zymeworks, together with development partner Jazz Pharmaceuticals, announced positive topline results from the Phase III HERIZON-GEA-01 trial of the HER2-directed bispecific zanidatamab in...
Merck spends $9.2B to buy Cidara — lung, flu prevention play
Merck agreed to acquire Cidara Therapeutics for $9.2 billion to add CD388, an investigational, long-acting, strain-agnostic antiviral designed to prevent symptomatic influenza in high-risk...
FDA clears menin inhibitor Komzifti — early approval for NPM1 AML
The FDA approved ziftomenib (Komzifti), an oral selective menin inhibitor developed by Kura Oncology and Kyowa Kirin, for treatment of relapsed or refractory (r/r) NPM1‑mutant acute myeloid...
Novo Nordisk readies Alzheimer verdict — semaglutide results due
Novo Nordisk is expected to announce key readouts from ambitious semaglutide studies testing whether the GLP‑1 agonist can slow Alzheimer’s disease progression. The company has flagged these...
White House vaccine shakeup — manufacturers warn of supply and schedule risk
U.S. vaccine manufacturers have privately warned federal officials that proposed changes under Health Secretary Robert F. Kennedy Jr.’s leadership—such as discouraging or banning certain adjuvants...
Nordic Capital buys Evosep — proteomics scales toward clinical markets
Private equity firm Nordic Capital acquired an 80% stake in Danish proteomics company Evosep to accelerate the company’s shift from research workflows into translational and clinical markets....
Nvidia, Sheba, Mount Sinai partner on genomic AI engine — gFM push
Nvidia, Sheba Medical Center’s ARC Innovation, and Mount Sinai’s Icahn School formed a three‑year collaboration to build a Genomic Foundation Model (gFM) — an LLM‑based platform designed to map...
J&J buys Halda for $3.05B — gains RIPTAC prostate drug and platform
Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash, adding Halda’s clinical‑stage RIPTAC platform and lead candidate HLD‑0915 to J&J’s oncology roster. Halda reported...
Arrowhead wins FDA OK for RNAi drug — rivals brace for price fight
Arrowhead Pharmaceuticals secured FDA approval for its RNA‑interference therapy plozasiran (Redemplo) for familial chylomicronemia syndrome, making Arrowhead a commercial‑stage RNAi company after...
Roche’s oral SERD hits primary goal — adjuvant breast‑cancer stakes rise
Roche reported positive Phase III results for giredestrant in the adjuvant setting, showing a statistically significant improvement in invasive disease‑free survival versus standard endocrine...
Zanidatamab posts Phase III win in gastroesophageal cancer — filing plans begin
Zymeworks’ HER2‑targeted bispecific zanidatamab (Ziihera) achieved its primary endpoint in the Phase III HERIZON‑GEA‑01 trial, demonstrating significant progression‑free survival (PFS) gains...
Administration mulls sweeping vaccine changes — industry issues private warnings
Reporting shows the Trump administration, guided by Health Secretary Robert F. Kennedy Jr., is considering policy changes that could restrict adjuvant use and reformulate multi‑disease combination...
Iambic, Terray land AI bets — models fuel discovery and candidate selection
Iambic closed a $100 million financing round to advance its Enchant and NeuralPLexer AI platforms, which the company says predict clinical endpoints and protein‑ligand structures to accelerate...
FDA clears ziftomenib (Komzifti) — menin inhibitor approved for NPM1‑mutant AML
The U.S. FDA approved ziftomenib (Komzifti), a selective oral menin inhibitor developed by Kura Oncology and Kyowa Kirin, for relapsed or refractory NPM1‑mutant acute myeloid leukemia (AML) ahead...